Overexpression of the c-Myc oncoprotein is observed in a large number of hematopoietic malignancies, and transgenic animal models have revealed a potent role for c-Myc in the generation of leukemias and lymphomas. However, the reason for high c-Myc protein levels in most cases is unknown. We examined whether aberrant protein stabilization could be a mechanism of c-Myc overexpression in leukemia cell lines and in primary bone marrow samples from pediatric acute lymphoblastic leukemia (ALL) patients. We found that c-Myc protein half-life was prolonged in the majority of leukemia cell lines and bone marrow samples tested. There were no mutations in the c-myc gene in any of the leukemia cell lines that could account for increased c-Myc stability. However, abnormal phosphorylation at two conserved sites, Threonine 58 and Serine 62, was observed in leukemia cell lines with stabilized c-Myc. Moreover, stabilized c-Myc from the ALL cell lines showed decreased affinity for glycogen synthase kinase3b, the kinase that phosphorylates c-Myc at Threonine 58 and facilitates its degradation. These findings reveal that deregulation of the c-Myc degradation pathway controlled by Serine 62 and Threonine 58 phosphorylation is a novel mechanism for increased expression of a potent oncoprotein known to be involved in hematopoietic malignancies.
Introduction
The c-myc proto-oncogene encodes a transcription factor that is critically involved in cell-fate decisions, including proliferation, differentiation and apoptosis. [1] [2] [3] [4] [5] Myc proteins are widely expressed during embryogenesis, and homozygous deletion of c-myc results in embryonic lethality. 6 In general, c-Myc promotes cell growth and proliferation, and reduced c-Myc expression appears to be necessary for terminal differentiation. [1] [2] [3] [4] [5] Therefore, control of c-Myc expression is vital to maintaining regulated cell proliferation in normal cells.
Deregulated c-Myc expression has been shown to play a significant role in cancer. Overexpression of c-Myc is observed in most human cancers, and transgenic animal models demonstrate c-Myc-induced tumorigenesis in multiple tissues, including leukemia and lymphoma. [7] [8] [9] [10] In addition, high c-Myc expression in many human hematopoietic malignancies has been correlated with a poor prognosis. 11 In Burkitt's lymphoma, increased c-myc transcription is driven by the t(8;14) translocation, which juxtaposes the immunoglobulin heavy-chain enhancer to the c-myc gene. 12 Also, c-myc gene amplification has been reported in some leukemia cell lines. 13 However, in most leukemias, the reason for c-Myc overexpression has not been elucidated.
c-Myc expression is tightly regulated in normal cells in response to growth stimulatory signals. Control of c-Myc expression occurs at transcriptional, post-transcriptional, translational and post-translational levels.
14-16 c-Myc protein rapidly accumulates when a quiescent cell is stimulated into the cell cycle. This transient increase in c-Myc protein levels, which potentiates S-phase entry, is enhanced by post-translational stabilization of the protein. 17 c-Myc levels subsequently diminish to low basal levels with progression through the cell cycle and continued proliferation. The clearance of c-Myc in continuously cycling cells and the maintenance of low levels in quiescent cells are largely owing to rapid ubiquitin-mediated proteolysis. 18, 19 The regulated stabilization and degradation of c-Myc protein is controlled by ordered phosphorylation at two specific sites near the N terminus of the protein: Serine 62 and Threonine 58. 20 Phosphorylation at these two sites occurs sequentially. 21 After a growth stimulatory signal, Serine 62 phosphorylation stabilizes c-Myc. Subsequent Threonine 58 phosphorylation promotes ubiquitylation and degradation by the 26S proteasome. 22, 23 Furthermore, removal of the stabilizing Serine 62 phosphate by protein phosphatase 2A (PP2A) facilitates the polyubiquitylation and degradation of c-Myc. 24 Phosphorylation at Serine 62 and Threonine 58 is regulated by two Ras-dependent pathways. 17, 20 Activation of the first pathway, the Raf/MEK/ERK (extracellular signal-regulated protein kinase) kinase cascade, can enhance c-Myc protein stability by ERK-mediated phosphorylation of Serine 62. The second pathway, involving phosphatidylinositol 3-kinase (PI(3)K) signaling, can also contribute to c-Myc stability by leading to the inhibition of glycogen synthase kinase (GSK)3b, which phosphorylates at Threonine 58. As growth stimulatory signals diminish, GSK3b becomes active and c-Myc is phosphorylated at Threonine 58. 25 Threonine 58 phosphorylation enhances PP2A-mediated removal of the Serine 62 phosphate and also allows recognition by the E3 ubiquitin ligase, SCF Fbw7 , which polyubiquitinates c-Myc and targets it for proteasome-mediated degradation. [22] [23] [24] This complex mechanism of post-translational control is important for regulated proliferation of normal cells.
Some evidence exists that disruption of the c-Myc degradation pathway controlled by Serine 62 and Threonine 58 phosphorylation may occur in cancer. For example, c-Myc that is mutated from Threonine to Alanine at position 58 shows impaired degradation and can facilitate the transformation of primary human cells. 20, 24 Moreover, this stable c-MycT58A mutant can accelerate lymphomagenesis in animal models. 26 Interestingly, point mutations at or adjacent to the c-Myc Threonine 58 phosphorylation site are frequently seen in human Burkitt's lymphoma. 27, 28 These mutations prevent phosphorylation at Threonine 58 and result in stabilized c-Myc protein in certain Burkitt's lymphoma cells. 19, 29, 30 Whether stabilization of c-Myc occurs in other human hematopoietic malignancies has not previously been reported.
In this study, we describe the presence of aberrant stabilization of c-Myc protein in human leukemia cells. We present evidence that overexpression of c-Myc in certain leukemia cell lines and primary patient samples correlates with prolonged c-Myc half-life. The increase in c-Myc half-life occurs in the absence of genetic alterations such as gene amplification or mutations in the c-myc coding sequence. Furthermore, we demonstrate that specific abnormalities in the phosphorylation/ dephosphorylation pathway that regulates c-Myc stabilization and degradation occur in some acute lymphoblastic leukemia (ALL) cell lines. These studies have therapeutic implications, as understanding the mechanism leading to aberrant expression of c-Myc could help direct identification of new targeted drugs.
Materials and methods

Cell lines
REH, SupB15, K562, HL-60 and CA46 cells were purchased from the American Type Culture Collection (Rockville, MD, USA). JY cells were a generous gift from Grover Bagby (OHSU). All leukemia cell lines and JY cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin and 2 mM L-glutamine at 371C in 5% CO 2 . Cells were kept between concentrations of 5 Â 10 5 /ml and 2 Â 10 6 /ml and were passed at least three times per week.
Primary cells
Consent was obtained from the Institutional Review Board at Oregon Health & Science University to obtain cryopreserved ficolled cells that were originally obtained by bone marrow aspiration at diagnosis from pediatric ALL patients. After thawing, cells were maintained in RPMI 1640 with 20% FBS and 2 mM L-glutamine for 16-20 h before performing assays.
Peripheral blood mononuclear cells (PBMCs) were prepared from human blood. For each preparation, 30 ml whole blood was drawn from a healthy volunteer donor into sterile ethylenediaminetetraacetic acid (EDTA) tubes, diluted 1:1 with Hank's balanced salt solution (BSS), and separated using Histopaque ficoll reagent. After centrifugation at 1400 r.p.m. for 30 min, the white cell layer was extracted. Cells were washed two times with Hank's BSS. Cells were maintained in RPMI 1640 medium with 20% FBS and 2 mM L-glutamine.
Fluorescent in situ hybridization
The leukemia cell lines were grown following standard protocols. Primary patient samples were cultured as above, except phytohemaglutinin was included in the culture medium. At the time of harvest, Colcemid (Sigma, St Louis, MO, USA) was added at a final concentration of 150 ng/ml. After 4-6 h, cells were trypsinized, placed in hypotonic media consisting of 5% FBS and 75 mM KCl, and fixed to slides. The slides were baked for 6 min at 901C in PBS, washed with 2 Â SSC at 371C for 30 min, dehydrated through graded alcohols and then airdried. Probes for c-myc (fluorescein isothiocyanate) and the centromeric region of chromosome 8 (CEP8) (Aqua) (Abbott Laboratories, Abbott Park, IL, USA) were mixed, denatured at 751C for 10 min and preannealed at 371C for 30 min. The probes were then added onto the slides, and hybridization was carried out using HYBrite (Vysis, Downers Grove, IL, USA; 721C denaturation temperature, 2 min denaturation time and reannealing at 371C overnight). The next day, the slides were washed with 0.4 Â SSC/0.1% NP-40 at 731C for 2 min, with 2 Â SSC/ 0.1% NP-40 (Sigma, St Louis, MO, USA) at room temperature for 1 min, and then counterstained with 125 mg/ml 4 0 ,6 0 -diamidino-2-phenylindole II (Vysis). Cells were observed using a Nikon E800 fluorescence microscope, and captured using CytoVision software from Applied Imaging (San Jose, CA, USA).
Antibodies and reagents
The c-Myc antibodies, N262 and C33, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The actin and tubulin antibodies are from Sigma (St Louis, MO, USA). The c-Myc Serine 62 phospho-specific antibody was prepared as described previously. 20 The Threonine 58 phospho-specific and GSK3b antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Lactacystin was obtained from EJ Corey Lab, Harvard University, and LY294002 was from purchased from EMD Biosciences (San Diego, CA, USA).
Western blotting and data quantitation
Cells were harvested using Ab lysis buffer (20 mM Tris (pH 7.5), 50 mM NaCl, 0.5% Nonidet P40, 0.5% sodium deoxycholate, 0.5% SDS, 1 mM EDTA, 10 mM sodium fluoride, 100 mM sodium vanadate, 1 mg/ml aprotinin, 1 mg/ml pepstatin, 0.5 mg/ml leupeptin, 0.2 mg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) and 1.6 mg/ml iodoacetamide). Protein concentration for each sample prepared with Ab lysis buffer was determined using BCA solutions kit (Sigma, St Louis, MO, USA). Alternatively, equal cell numbers were lysed in SDS sample buffer and adjusted for equal actin levels. Equal protein for each sample was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P or Immobilon-FL membrane (Millipore, Billerica, MA, USA). Membranes were blocked using Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) or 5% non-fat milk in PBS with 0.05% Tween-20. Primary antibodies were in Odyssey blocking buffer, except for anti-phospho-Threonine 58, which was in 2.5% nonfat milk. Primary antibodies were detected using secondary antibodies labeled with the near-infrared fluorescent dyes IRDye800 (Rockland, Philadelphia, PA, USA) and Alexa Fluor 680 (Molecular Probes, Eugene, OR, USA) to allow two-color imaging and band overlay. Secondary antibodies were diluted 1:10 000 in Odyssey blocking buffer, and blots were scanned with a LI-COR Odyssey Infrared Imager (Lincoln, NE, USA) to visualize proteins and allow simultaneous anti-rabbit and antimouse dual wavelength detection. Band intensities for Western blots were quantitated after background subtraction using LI-COR Odyssey Infrared Imager software version 1.2, which allows for linear protein concentration analysis over four orders of magnitude. Error bars were calculated using Excel (Microsoft, Redmond, WA, USA).
Sequencing the c-myc coding region
Total RNA was isolated from each cell line and subjected to reverse transcription to generate cDNA followed by PCR to c-Myc protein stabilization in leukemia S Malempati et al amplify the entire c-myc coding region, which was then sequenced.
Pulse-chase experiments
Cells were placed in Dulbecco's modified Eagle's medium (DMEM) lacking L-methionine and L-cysteine with 10% dialyzed FBS for 15 min. Cells were then labeled in vivo with 35 Smethionine/cysteine (Perkin-Elmer, Boston, MA, USA) in DMEM medium (-L-met/L-cys) with 10% dialyzed FBS for 20-30 min for leukemia cell lines and JY cells, and 2-4 h for primary leukemia bone marrow cells, ficolled normal bone marrow cells and PBMCs owing to their slow metabolic rate. Cells were then washed one time with 'chase' medium consisting of RPMI with 10% FBS, 5 mM L-methionine and 3 mM L-cysteine. Equal numbers of cells were incubated in the chase media for the indicated chase times and then harvested in Ab lysis buffer as described previously. 17 Labeled c-Myc was immunoprecipitated from an equal number of cells for each time point using the c-Myc C33 monoclonal antibody-conjugated beads (Santa Cruz Biotechnology). Immunoprecipitated c-Myc was separated by SDS-PAGE, and labeled c-Myc was quantitated using a phosphorimager as described previously. 17 After background subtraction, band intensity was plotted on a log scale for each time point using Microsoft Excel graphing function, and c-Myc half-life was determined from the exponential line equation.
Co-immunoprecipitation
Equal cell numbers were lysed in 10 Â cell volumes of Coimmunoprecipitation (Co-IP) buffer (20 mM Tris, pH 7.5, 12.5% glycerol, 0.2% NP-40, 200 mM NaCl, 1 mM EDTA, 1 mM ethyleneglycol tetraacetate, 1 mM dithiothreitol, 10 mM sodium fluoride, 100 mM sodium vanadate, 1 mg/ml aprotinin, 1 mg/ml pepstatin, 0.5 mg/ml leupeptin, 0.2 mg/ml AEBSF and 1.6 mg/ml iodoacetamide) and pre-cleared with protein A þ G agarose (Calbiochem, San Diego, CA, USA). Samples were then incubated with either 1:50 dilution of anti-c-Myc (C33)-conjugated beads (Santa Cruz Biotechnology) or control protein A þ G agarose. Precipitated proteins were washed three times in 10 Â cell volumes of Co-IP buffer, released by boiling in SDS sample buffer and separated by SDS-PAGE. Gels were transferred and Western blot analysis was performed.
Results
c-Myc is overexpressed in leukemia cell lines without c-myc gene amplification or coding sequence mutations
Overexpression of c-Myc has been reported in most cancers, including various types of leukemia. 2, 11, 31, 32 In some cases, c-myc gene amplification has been described. We assessed c-myc gene status and c-Myc protein expression in two precursor B-ALL cell lines (REH and SupB15), one acute myelogenous leukemia (AML) cell line (HL-60) and one chronic myeloid leukemia (CML) cell line (K562). To evaluate the presence of c-myc gene amplification in the four leukemia cell lines, the OHSU Cytogenetics laboratory performed fluorescence in situ hybridization (FISH) using a c-myc probe ( Figure 1a ). Consistent with previous reports, we found amplification of the c-myc gene, in the form of a large block of c-myc signal-positive material, on a chromosome other than chromosome 8 in the HL-60 cell line (red arrows). 13 Conversely, none of the three remaining cell lines had either large blocks of amplified sequence or double minutes detected by FISH with the c-myc probe. Two normal c-myc signals were seen on chromosome 8 in the SupB15 cell line. One extra c-myc signal was seen in the K562 cell line owing to trisomy 8. Two extra copies of c-myc were located on chromosomes other than chromosome 8 without gene amplification in the REH cell line. Therefore, only in the HL-60 cell line did we find evidence of c-myc gene amplification. We next assessed c-Myc protein levels in the four leukemia cell lines by Western blotting. We found elevated levels of c-Myc protein in all four of the leukemia cell lines, with the highest levels in the HL-60 cells (Figure 1b) . In contrast, both normal PBMCs from a healthy donor and the Epstein-Barr Virus (EBV)-transformed human B-lymphocyte cell line, JY, showed very low c-Myc protein levels. Our observation of high c-Myc levels in all four leukemia cell lines corroborates previous reports of c-Myc overexpression in leukemia cells. 11, 31 However, with the exception of HL-60 cells that have amplified c-myc, the reason for elevated c-Myc levels in these leukemia cell lines is unclear.
To examine the mechanism of increased c-Myc expression in the leukemia cell lines without c-myc gene amplification, we initially looked for mutations that could affect c-Myc protein turnover. Mutations in the coding region of c-myc at or adjacent to Threonine 58 result in impaired proteasome-mediated degradation and are frequently found in Burkitt's lymphoma and AIDS-associated lymphomas. 27, [33] [34] [35] To discover whether mutations exist in the leukemia cell lines under study, we sequenced the entire c-myc coding region in each of the four leukemia lines. No coding sequence mutations were found (Figure 1c) . Taken together, these results suggest that the c-Myc overexpression observed in some leukemia cell lines can occur in the absence of c-myc genetic alterations.
c-Myc protein is stabilized in leukemia cell lines without c-myc mutations or gene amplification
Post-translational control of c-Myc protein stability is important for preventing overexpression of the oncoprotein in normal cells. 36 To assess whether aberrant stabilization of c-Myc REH, SupB15, K562 and HL-60 cells were treated for 4 h with lactacystin, a specific inhibitor of the 26S proteasome. As shown in Figure 2c , proteasome inhibition had only a modest effect on c-Myc levels in the three leukemia cell lines (REH, SupB15 and K562) where c-Myc is more stable (lanes 1-6) . In contrast, a substantial increase in c-Myc protein was seen with lactacystin treatment of HL-60 cells (Figure 2c, lanes 7 and 8) . Thus, while HL-60 cells have increased expression of c-Myc protein owing to c-myc gene amplification, the marked increase in c-Myc upon proteasome inhibition reflects the instability and normal rapid turnover of c-Myc in these cells. These findings suggest that in the three cell lines that show less of an effect with lactacystin, a perturbation exists upstream of 26S proteasome-mediated degradation, which results in prolonged c-Myc half-life.
The levels of Serine 62 and Threonine 58 phosphorylated c-Myc are altered in leukemia cell lines with stable c-Myc protein
Previous experiments have shown that Serine 62 phosphorylation precedes Threonine 58 phosphorylation in the normal c-Myc degradation pathway. 20, 21 However, polyubiquitinated c-Myc is primarily phosphorylated at Threonine 58, with little Serine 62 phosphorylation. 20, 24 Therefore, both Threonine 58 phosphorylation and subsequent dephosphorylation at Serine 62 are important for polyubiquitylation and timely degradation of c-Myc. 24 We assessed the phosphorylation status of c-Myc at Serine 62 and Threonine 58 in the leukemia cell lines under investigation using phospho-specific antibodies. Double labeling for total and phosphorylated c-Myc allowed us to quantitate the ratio of phospho-Serine 62 c-Myc to total c-Myc and phospho-Threonine 58 c-Myc to total c-Myc (Figure 3, graph) . lanes 1-4) or the C33 antibody and phosho-T58-c-Myc antibody (rabbit) (lanes 6-9), using different IRDye secondary antibodies for detection (see Materials and methods). The Western blots shown are representative of three independent experiments. The amount of signal from each antibody was detected and quantitated using an Odyssey Infrared Imager and software from LI-COR Biosciences (see Materials and methods). The bar graph (with s.e.) shows the mean ratio from the three experiments of Theonine 58 phospho-specific signal to total c-Myc signal in black and the mean ratio of Serine 62 phosphospecific signal to total c-Myc signal in gray for the four leukemia cell lines. Phospho-Serine 62 and phospho-Threonine 58 signal in the CA46 Burkitt's lymphoma with a known proline to serine mutation at position 57 is also shown (lanes 5 and 10, and graph).
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As shown in Figure 3 , in HL-60 cells, we detected very little Serine 62-phosphorylated c-Myc, while Threonine 58-phosphorylated c-Myc was clearly evident (lanes 2 and 9, and graph). This finding is consistent with previous experiments examining the phosphorylation status of unstable c-Myc in other cell types, and suggests that c-Myc in HL-60 cells is rapidly processed through the Serine 62 phosphorylation/Threonine 58 phosphorylation/Serine 62 dephosphorylation degradation pathway. 20 In contrast, in the leukemia cell lines in which we observe more stable c-Myc protein, we consistently see a substantially higher level of Serine 62-phosphorylated c-Myc, whereas Threonine 58-phosphorylated c-Myc appears on average somewhat lower than that observed in the HL-60 cells (Figure 3, lanes 1,3,4, 6-8, and graph) . This increased level of Serine 62-phosphorylated c-Myc and somewhat lower level of Threonine 58-phosphorylated c-Myc, as compared to unstable c-Myc from HL-60 cells, is most evident in the REH and SupB15 ALL cell lines, which had the longest c-Myc half-life (Figure 2b) . These results suggest that the c-Myc degradation pathway, controlled by Serine 62 and Threonine 58 phosphorylation, is perturbed in leukemia cell lines with prolonged c-Myc half-life.
We also observed high levels of Serine 62-phosphorylated c-Myc in the absence of Threonine 58 phosphorylation in the CA46 Burkitt's lymphoma cell line (Figure 3 , lanes 5 and 10, and graph), which has a known c-myc mutation at the codon for Proline 57 (Figure 1c ). This Proline 57 to Serine mutation has previously been shown to prevent phosphorylation at Threonine 58, and to be associated with impaired c-Myc degradation in the CA46 cell line. 29 Moreover, we and others have previously shown that Serine 62 phosphorylation is enhanced in a Threonine 58 to Alanine c-Myc mutant, and that a high degree of Serine 62 phosphorylation correlates with stabilized c-Myc protein. 17, 20, 21, 24 Similarly, in leukemia cell lines in this study, detection of high Serine 62 phosphorylation and lower Threonine 58 phosphorylation, relative to HL-60 cells, correlates with increased c-Myc stability. However, as we have shown that these leukemia cell lines do not have c-myc mutations at or near the Threonine 58 phosphorylation site (Figure 1c) , the reason for increased Serine 62 phosphorylation is not apparent.
Activation of PI(3)K is important for aberrant stabilization of c-Myc in two ALL cell lines
In order to examine possible mechanisms underlying the altered phosphorylation and increased c-Myc stabilization we observe in some leukemia cell lines, we focused on the two ALL cell lines that showed the most dramatic change in Serine 62 and Threonine 58 phosphorylation: REH and SupB15. We evaluated the kinase pathways that have been reported to regulate the phosphorylation of Serine 62 and Threonine 58. Upon serum stimulation in normal cells, activation of the Ras/Raf/MEK/ERK cascade can phosphorylate Serine 62 and activation of the Ras/ PI(3)K/AKT pathway can inhibit GSK-3b, which would decrease phosphorylation at Threonine 58. Both Ras-activated pathways promote transient accumulation of c-Myc in murine fibroblasts. 17 Examination of phosphorylated ERK and AKT in the REH and SupB15 cell lines revealed no increase in ERK or AKT activity that would explain the altered phosphorylation at Serine 62 and Threonine 58 (data not shown). However, both the REH and SupB15 cell lines are reported to have hemizygous deletion of the PTEN gene, which encodes the phosphatase that counteracts PI(3)K activity. 39 PTEN protein levels were shown to be severely reduced in the REH and SupB15 cells, which should lead to hyperactivity of PI(3)K, although this was not associated with increased AKT activation, 39 consistent with our results.
We examined whether activity of PI(3)K could contribute to increased c-Myc stability in the REH and SupB15 cell lines. We inhibited PI(3)K with the LY294002 compound and assessed affects on c-Myc accumulation in the REH and SupB15 cells, compared to the HL-60 cells, which do not have a PTEN gene deletion. After treating the cell lines with LY294002, we saw a significant decrease in c-Myc levels in the REH and SupB15 cell lines, but not in the HL-60 cell line (Figure 4a, lanes 1 and 2, all  panels) . This finding suggests that activity of PI(3)K is necessary to maintain high c-Myc expression in REH and SupB15 cells, but not in HL-60 cells. To ascertain whether the decrease in c-Myc levels upon PI(3)K inhibition is owing to an increase in c-Myc 
The drop in c-Myc protein with PI(3)K inhibition was, at least to some degree, abrogated by concomitant proteasome inhibition in the REH and SupB15 cells (Figure 4a, lane 3) . This finding shows that the full effect of PI(3)K inhibition on c-Myc levels requires proteasome-mediated degradation of c-Myc, and it suggests that increased activation of the PI(3)K pathway in REH and SupB15 cell lines plays a role in the aberrant stabilization of c-Myc.
Impaired c-Myc degradation correlates with decreased GSK3b interaction with c-Myc
We next assessed whether GSK3b activity toward c-Myc is altered in the REH and SupB15 ALL cells. As recent reports bring into question the role of Serine 9 phosphorylation on GSK3b as a marker of its activity toward targets not involved in insulin signaling, 40, 41 we chose not to base our assessment of GSK3b function on Serine 9 phosphorylation status. Rather, we directly assessed GSK3b activity toward c-Myc in the leukemia cell lines by examining the ability of GSK3b to associate with c-Myc. We performed c-Myc Co-IP assays from total cell lysates of equal numbers of HL-60, REH and SupB15 cells. As shown in Figure 4b , we observed a stable interaction between GSK3b and c-Myc that could be detected by Co-IP with the c-Myc antibody in the HL-60 cell line, where c-Myc is relatively unstable (lower panel, lane 2). In contrast, very little GSK3b was pulled down with c-Myc in the REH and SupB15 cells where c-Myc is stabilized (lower panel, lanes 4 and 6), even though these ALL cell lines had more GSK3b in their input cell lysates (upper right panel). Although GSK3b can clearly still phosphorylate c-Myc at Threonine 58 in the REH and SupB15 cells, the decreased, or unstable interaction of GSK3b with c-Myc in these cells could lead to the reduction in Threonine 58 phosphorylation that we observe (Figure 3 ). In addition, as Threonine 58 phosphorylation facilitates PP2A-mediated dephosphorylation of Serine 62, 24 this defect in GSK3b function could allow for the observed accumulation of Serine 62-phosphorylated c-Myc in the REH and SupB15 ALL cell lines. Taken together, these results demonstrate that both activation of PI(3)K and decreased interaction with GSK3b contribute to increased c-Myc stability in the ALL cells, although the exact connection between PI(3)K signaling and GSK3b activity toward c-Myc remains unclear.
c-Myc is stabilized in primary ALL cells from pediatric patients
In order to determine whether c-Myc stabilization occurs in primary leukemia cells from patients, we obtained 10 banked bone marrow samples from pediatric patients with precursor B-cell or T-cell ALL and three banked normal bone marrow samples as controls. Sufficient cells were present in six of the ALL samples and three of the normal marrow samples to do pulse-chase analyses. In addition, four of the six ALL samples had enough cells to perform FISH to look for evidence of c-myc genetic changes. None of the previously frozen bone marrow samples proliferated in culture and no metaphase cells were observed in the presence of Colcemid. The cells were also not undergoing apoptosis or dying during our culturing period (data not shown). We measured c-Myc protein half-life in the six pediatric ALL bone marrow samples with sufficient material and the three normal bone marrow samples for comparison. Table 1 . These results indicate that aberrant stabilization of c-Myc protein can occur in some cases of pediatric ALL, and that protein stabilization does not correlate with any obvious c-myc genetic changes.
Discussion
Control of c-Myc expression occurs at multiple levels in normal cells. Transcriptional regulation, post-transcriptional stabilization of mRNA and post-translational control of protein stability are all known to play a role in determining c-Myc levels. 36 Our previous work has revealed a complex pathway that controls c-Myc protein stabilization and degradation in response to cell proliferative signals and cell cycle entry. 20, 24 The data presented in this report shows that aberrant stabilization of c-Myc owing to perturbations of this complex degradation pathway occurs in some human leukemia cells.
Our experiments revealed that c-Myc protein is stabilized in a CML and several pre-B ALL cell lines as well as in primary pediatric pre-B-and T-cell ALL bone marrow samples. In contrast, the HL-60 AML cell line overexpressed c-Myc owing to gene amplification and not protein stabilization. It is intriguing that c-Myc degradation could occur at a normal rate in a cell line with c-myc gene amplification, where very high c-Myc protein levels might be expected to overwhelm the degradation machinery. Adaptation to high c-Myc expression could be an explanation. Although the HL-60 AML cell line did not have stabilized c-Myc, it is quite possible that c-Myc is stabilized in other AML cell lines or primary AML cells. Indeed, an initial analysis of the AML cell line, CTV-1, reveals a half-life for c-Myc of 147 min (data not shown). Moreover, three additional cell lines F MOLT-3, CCRF-CEM (T-cell ALLs) and HEL (erythroleukemia) F reveal half-lives for c-Myc ranging from 53 to 58 min (data not shown). While this report focuses on four leukemia cell lines and six pediatric ALL bone marrow samples, our results lay down an important framework that will set the stage for future analyses of c-Myc protein stabilization in a larger study of primary human leukemias and in other human cancers.
Previous reports have revealed that prolonged c-Myc half-life in certain Burkitt's lymphoma cells is owing to mutations at or near the Threonine 58 phosphorylation site. [28] [29] [30] We found no such mutations in any of the leukemia cell lines evaluated in this study. Our results in the REH, SupB15 and K562 leukemia cell lines represent the first report that we are aware of showing aberrant c-Myc protein stabilization in human cancer without a coding sequence mutation in the c-myc gene.
Assessment of phosphorylation at Serine 62 and Threonine 58 in leukemia cells with stabilized c-Myc as compared to cells with normal c-Myc degradation helped to delineate a potential mechanism underlying c-Myc stabilization. We know from previous experiments and other reports that Threonine 58 phosphorylation and subsequent Serine 62 dephosphorylation are important for ubiquitylation and proteasome-mediated degradation of c-Myc. 20, [22] [23] [24] [25] However, the leukemia cell lines with stabilized c-Myc showed the inverse pattern of phosphorylation, with markedly higher levels of Serine 62-phosphorylated c-Myc and somewhat reduced levels of Threonine 58 phosphorylation.
In our analysis of the mechanisms contributing to c-Myc stabilization, we demonstrated a role for the activation of the PI(3)K pathway in REH and SupB15 ALL cells. These cell lines have hemizygous deletion of the PTEN gene, encoding the phosphatase that reverses PI(3)K function, which should lead to increased PI(3)K activity. 39 Another recent study also described that increased PI(3)K activity, owing to reduced expression of PTEN, correlated with c-Myc overexpression in pancreatic cancer cells. 42 In addition, our experiments showed a striking decrease in the association of GSK3b with c-Myc in the REH and SupB15 cells. Based on studies involving insulin signaling, AKT, which is activated by PI(3)K signaling, inhibits GSK3b by phosphorylating it on Serine 9. 43 However, in our studies, REH and SupB15 cells did not show increased AKT activity (data not shown), consistent with the report describing hemizygous deletion of PTEN in these cells. 39 It is possible that a highly homologous kinase, SGK, which is also activated by PI(3)K and can inactivate GSK3b, is responsible for the impaired GSK3b activity toward c-Myc in the ALL cell lines. 44 On the other hand, recent reports have suggested that GSK3b activity on certain targets, such as b-catenin, is not affected by Serine 9 phosphorylation. 40, 41 Thus, while our data clearly implicate Twenty nine of the 100 cells had four signals for c-myc and four for CEP8, indicating tetrasomy 8, 10/100 cells showed trisomy 8 with three signals for c-myc and three for CEP8, 57/100 showed normal two c-myc, two CEP8 and 4/100 showed one c-myc and two CEP8. c-Myc protein stabilization in leukemia S Malempati et al PI(3)K activity and GSK3b inhibition as mechanisms in c-Myc stabilization in the ALL cell lines, the exact link between PI(3)K and GSK3b in these leukemia cells remains to be elucidated.
Mechanistically, decreased association between GSK3b and c-Myc could explain the high Serine 62 phosphorylation and partial reduction in Threonine 58 phosphorylation observed in the ALL cell lines. Previous data shows that without Threonine 58 phosphorylation, PP2A cannot dephosphorylate Serine 62. 24 Thus, a decrease in Threonine 58 phosphorylation could both increase Serine 62 phosphorylation levels and decrease SCF Fbw7 -mediated polyubiquitylation of c-Myc, resulting in the accumulation of stabilized c-Myc that is phosphorylated at Serine 62 in the ALL cell lines.
Along with finding evidence of impaired c-Myc degradation in leukemia cell lines and providing insight into the mechanism behind this impaired degradation, we show that c-Myc stabilization occurs in primary leukemia cells from pediatric patients with ALL. It would be of interest to expand this study in the future to look for the frequency of impaired c-Myc degradation and determine whether any correlation exists with clinical outcome. However, this would require a much larger cohort of leukemia patients. To our knowledge, this is the first report of aberrant c-Myc protein stabilization in primary human leukemia cells.
In summary, our findings reveal a previously unrecognized mechanism for overexpression of c-Myc in some human leukemias that relies on alteration in cellular factors other than c-Myc itself. Additionally, our analysis of the mechanism underlying c-Myc stabilization in certain leukemia cell lines suggests that the Threonine 58/Serine 62 phosphorylation/ dephosphorylation pathway that controls c-Myc degradation can become deregulated in human leukemia, and that this pathway may constitute a novel therapeutic target in hematopoietic malignancies that have stabilized c-Myc.
